Valuation: Alkermes plc

Market Cap 7.9B 7.16B 6.62B 5.98B 11.26B 745B 11.66B 79.57B 31.55B 398B 29.66B 29.03B 1,264B P/E 2026 *
-96.5x
P/E 2027 * 105x
Enterprise Value 8.96B 8.12B 7.51B 6.78B 12.77B 845B 13.22B 90.23B 35.78B 451B 33.63B 32.92B 1,433B EV / Sales 2026 *
4.91x
EV / Sales 2027 * 4.54x
Free-Float
89.46%
Yield 2026 *
-
Yield 2027 * -
1 day+0.11%
1 week+2.46%
Current month+3.73%
1 month+17.28%
3 months-4.14%
6 months+25.48%
Current year+68.08%
1 week 45.27
Extreme 45.27
48.3
1 month 41.35
Extreme 41.35
48.3
Current year 27
Extreme 27
55.67
1 year 27
Extreme 27
55.67
3 years 22.22
Extreme 22.22
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 53 01/08/2026
Director/Board Member 74 26/05/2016
Date Insider Type Main position Quantity % Market Cap. Importance
3/11/26 Sell

Compliance Officer

-2,035 0.0012%
8/10/26 Exercice

Chief Financial Officer

22,397 0.0134%
7/10/26 Free

Director

25,237 0.0150%
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%+2.46%+61.95%+98.36% 7.9B
+1.26%+6.61%+40.79%+145.27% 1,286B
+0.79%+3.45%+45.84%+92.04% 688B
+0.20%+1.28%+26.97%+114.41% 521B
-0.44%+3.69%+41.45%+70.04% 386B
+0.55%+0.70%+59.02%+45.79% 364B
-0.12%+0.74%+28.39%+60.32% 302B
+0.37%+0.37%+3.33%+38.57% 287B
-0.30%+1.14%+38.29%+70.56% 252B
+0.08%+0.71%+34.44%+123.99% 208B
Average +0.25%+2.12%+38.05%+85.93% 430B
Weighted average by Cap. +0.54%+3.25%+37.74%+99.28%

Financials

2026 *2027 *
Net sales 1.82B 1.65B 1.53B 1.38B 2.6B 172B 2.69B 18.37B 7.28B 91.88B 6.85B 6.7B 292B 1.92B 1.74B 1.61B 1.46B 2.74B 181B 2.84B 19.38B 7.68B 96.92B 7.22B 7.07B 308B
Net income -85.44M -77.42M -71.61M -64.61M -122M -8.06B -126M -860M -341M -4.3B -321M -314M -13.66B 82.17M 74.46M 68.87M 62.14M 117M 7.75B 121M 827M 328M 4.14B 308M 302M 13.14B
Net Debt 1.06B 959M 887M 800M 1.51B 99.79B 1.56B 10.66B 4.23B 53.31B 3.97B 3.89B 169B 840M 762M 704M 636M 1.2B 79.24B 1.24B 8.46B 3.36B 42.33B 3.15B 3.09B 134B
Projected Income Statement - Annual - Alkermes plc
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
13/11/26 USD 47.03 +0.11% 1,429,845
12/11/26 USD 46.98 -1.90% 3,125,557
11/11/26 USD 47.89 +3.06% 1,031,864
10/11/26 USD 46.47 +0.65% 1,035,990
09/11/26 USD 46.17 +0.59% 1,709,146
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Alkermes plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
47.03USD
Average target price
57.74USD
Spread / Average Target
+22.77%
  1. Stock Market
  2. Stocks
  3. ALKS Stock